Use of Neoadjuvant Vandetanib in Aggressive Pediatric Medullary Thyroid Carcinoma

JCO Precis Oncol. 2024 Jan:8:e2300257. doi: 10.1200/PO.23.00257.

Ronik Kothari¹, Sara Kreimer^{2

3}, Helen Nadel^{2

4}, Hilary Seeley^{2

5}, Gary Hartman^{2

6}, Kara D Meister^{2

7}

¹ California University of Science and Medicine, Colton, CA.
² Children's Thyroid Clinic at Stanford Medicine Children's Health, Palo Alto, CA.
³ Pediatric Oncology and Hematology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA.
⁴ Division of Pediatric Nuclear Medicine, Department of Radiology, Stanford University School of Medicine, Palo Alto, CA.
⁵ Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA.
⁶ Division of Pediatric Surgery, Department of Surgery, Stanford University School of Medicine, Palo Alto, CA.
⁷ Division of Pediatric Otolaryngology, Department of Otolaryngology-Head & Neck Surgery, Stanford University School of Medicine, Palo Alto, CA.

Abstract

Novel use of vandetanib in a child with aggressive MTC with prolonged response to treatment.